- Home
- CHRS vs INZY Comparison
CHRS vs INZY Comparison
Compare CHRS & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- INZY
- Stock Information
- Founded
- CHRS 2010
- INZY 2015
- Country
- CHRS United States
- INZY United States
- Employees
- CHRS N/A
- INZY N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- INZY Health Care
- Exchange
- CHRS Nasdaq
- INZY Nasdaq
- Market Cap
- CHRS 191.3M
- INZY 188.2M
- IPO Year
- CHRS 2014
- INZY 2020
- Fundamental
- Price
- CHRS $1.55
- INZY $1.54
- Analyst Decision
- CHRS Strong Buy
- INZY Strong Buy
- Analyst Count
- CHRS 4
- INZY 8
- Target Price
- CHRS $5.38
- INZY $17.75
- AVG Volume (30 Days)
- CHRS 2.3M
- INZY 666.9K
- Earning Date
- CHRS 11-06-2024
- INZY 11-05-2024
- Dividend Yield
- CHRS N/A
- INZY N/A
- EPS Growth
- CHRS N/A
- INZY N/A
- EPS
- CHRS N/A
- INZY N/A
- Revenue
- CHRS $304,340,000.00
- INZY N/A
- Revenue This Year
- CHRS $2.47
- INZY N/A
- Revenue Next Year
- CHRS N/A
- INZY N/A
- P/E Ratio
- CHRS N/A
- INZY N/A
- Revenue Growth
- CHRS 44.19
- INZY N/A
- 52 Week Low
- CHRS $0.66
- INZY $1.62
- 52 Week High
- CHRS $2.97
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- CHRS 55.21
- INZY 22.68
- Support Level
- CHRS $1.44
- INZY $2.68
- Resistance Level
- CHRS $1.77
- INZY $3.18
- Average True Range (ATR)
- CHRS 0.13
- INZY 0.27
- MACD
- CHRS -0.02
- INZY -0.11
- Stochastic Oscillator
- CHRS 50.00
- INZY 1.87
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.